October 20, 2026
October 20, 2026
Story by Dean Parthenis | Video by Francis Silvaggio
LETHBRIDGE — When David Lunn reflects on his prostate cancer diagnosis, his memories reach far beyond the treatment room.
He remembers appointments, travel and disruption that came with his own treatment for prostate cancer.
“It really is that balance, the most effective treatment with the least amount of both side-effects and I guess interference with your regular life,” says Lunn, a current patient advisor with Cancer Care Alberta.
Now, a clinical trial at Lethbridge’s Jack Ady Cancer Centre (part of Cancer Care Alberta), is exploring whether some patients with intermediate to high-risk prostate cancer could eventually receive highly personalized radiation treatment in as few as two sessions.
Supported by the Alberta Cancer Foundation through a significant donation from the Chinook Regional Hospital Foundation, the Dose Adapted Personalized Ablative Radiotherapy trial (DAPAR) is examining whether advanced imaging can help make radiation treatment more responsive to each individual patient’s cancer.
“Traditionally, we prescribe a course of radiation based on the available population data, and then we follow it through,” says Dr. Charles Kirkby, a senior medical physicist with Cancer Care Alberta at the Jack Ady Cancer Centre. “The focus of the DAPAR research is to track individual patients’ responses, and adjust treatment accordingly.”
Conventional radiation treatment for prostate cancer can involve 39 daily treatments over several weeks. The DAPAR trial’s use of magnetic resonance imaging, or MRI, will better assess how each patient responds after the first treatment, therefore potentially reducing the number of treatments each patient may need to successfully treat their cancer.
“With the trial, based on how a patient responds to that first treatment, we can provide a second adapted treatment where we scale the dose based on that response,” says Kirkby, the principal investigator of the trial. For patient Darrell Nason, who will be the first to participate in the new clinical trial, the possibility of fewer appointments and an approach tailored to his specific cancer resonates strongly.
“The program could reduce the number of patient treatments, vehicle travel, time off work and stress, all resulting in families having more time to spend with their loved ones,” says Nason.
The trial will involve 52 patients in two groups. One will receive the current five-treatment Stereotactic Body Radiotherapy (SBRT) approach while the other will receive the new two-treatment approach being studied. The initial purpose is to demonstrate that the approach can be delivered safely; larger studies would be needed to determine its longer-term effectiveness in controlling cancer.
For Kirkby, who also holds appointments with the Universities of Calgary and Lethbridge, the achievement represents years of work to build research capacity at the Jack Ady Cancer Centre since its opening in 2010. When he accepted the position, Kirkby recalls being uncertain as to whether there would be capacity for research in Lethbridge.
“As you can imagine, I took that as a challenge,” he says.
The DAPAR trial is the first investigator-initiated radiation therapy clinical trial to take place at a regional cancer centre in Alberta.
“It’s important that access to clinical trials is not limited to Albertans who live in Calgary and Edmonton,” Kirkby says.
The work supports Alberta’s Strategic Plan for Cancer to 2036 and Cancer Care Alberta’s role in making innovative cancer care more accessible across the province.
The trial, run through the Arthur J.E. Child Comprehensive Cancer Centre’s Owerko Family Centre for Clinical Trials, was selected through the Alberta Cancer Foundation 2025 Game Changer Competition. The Chinook Regional Hospital Foundation’s donation helps fund the dedicated nursing staff, coordination and specialized MRI time at the University of Lethbridge affiliated U3T MRI Centre needed to run it safely.
Says Wendy Beauchesne, CEO of the Alberta Cancer Foundation, “the support is helping build research capacity in southern Alberta and creating new opportunities for patients to access innovative cancer care closer to where they live.”